Sumary of CEO of Covid antibody maker Vir Biotech says their treatment ‘stands up well’ to all variants:
- A monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline “stands up well” to all variants of the virus, Vir President and CEO George Scangos told CNBC’s “Power Lunch” on Wednesday.
- Scangos’ comments came after the two companies announced contracts to sell $1 billion worth of their antibody, sotrovimab, to the U.S. government.
- The Food and Drug Administration granted sotrovimab an emergency use authorization in May to treat up to moderate Covid infections in adults and children.
- “It certainly is an effective antibody against Covid, but also against SARS, also against many other coronaviruses,” Scangos said.
- Science Though Scangos said that the highly transmissible delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge moving forward.
- Future mutations could even be variants of delta itself, Scangos said, similar to the delta plus subvariant that officials in the U.K. started monitoring in a rising number of cases this fall.